Photo by bermixstudio from unsplash
Many cancers lack the expression of methylthioadenosine phosphorylase (MTAP). These cancers require adenylosuccinate synthetase (AdSS) for nucleic acid synthesis. By inhibiting adenylosuccinate synthetase, we potentially have a new therapeutic agent.… Click to show full abstract
Many cancers lack the expression of methylthioadenosine phosphorylase (MTAP). These cancers require adenylosuccinate synthetase (AdSS) for nucleic acid synthesis. By inhibiting adenylosuccinate synthetase, we potentially have a new therapeutic agent. Bisubstrate inhibitors were synthesized and evaluated against purified AdSS. The best activity was obtained with adenosine bearing a four‐carbon linker that connects the N‐formyl‐N‐hydroxy moiety to the 6‐position of the purine nucleoside.
Journal Title: ChemMedChem
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!